Science Corporation, a full-stack neural engineering company dedicated to restoring and extending life through advanced brain-computer interface (BCI) technologies, has entered a multiyear, multimillion-dollar partnership with Neurosoft Bioelectronics to bring Neurosoft full access to the Science BCI Ecosystem, a comprehensive suite of clinical-grade neural recording tools that dramatically lowers the cost, complexity and timeline of developing BCI products and enables innovators to focus on therapeutic breakthroughs rather than core hardware infrastructure, with the alliance expected to cut the cost of bringing first-in-human trials from an estimated $75–100 million to under $5 million and accelerate patient-ready solutions for conditions such as tinnitus, epilepsy and other neurological disorders while advancing high-fidelity neural data collection for AI-driven neurotechnology applications.
Also Read: Transcarent Unveils Advanced AI-Driven Features for Its WayFinding™ 2.0 Health Platform
Max Hodak, CEO and cofounder of Science, said: “We recognize that neural engineering breakthroughs happen at the intersection of diverse expertise. By providing robust, modular building blocks designed to meet the requirements of the most rigorous modern BCI applications, we are enabling innovation leaders across the BCI industry to develop targeted therapeutic solutions without rebuilding fundamental infrastructure, ultimately bringing transformative therapies to patients faster.” Nicolas Vachicouras, PhD, CEO and cofounder of Neurosoft, added: “This partnership with Science is a strategic move that aggressively accelerates clinical adoption, bringing potentially life-changing therapies to patients faster than ever seen before in the industry, while rapidly scaling the high-fidelity neural data collection essential for powering Neurosoft’s foundation AI models,” underscoring the strategic value of combining Science’s modular platform with Neurosoft’s ultra-soft, fully implantable interface technology in advancing both clinical and AI-enabled BCI innovation. Darius Shahida, Chief Strategy Officer at Science, noted: “Neurosoft is the ideal partner to debut this model…reflects Science’s broader vision to foster a community of BCI innovators working toward life-changing therapies for neurological injury and disease, and to advance the field by reducing development cost and complexity. Our multiyear, multimillion dollar agreement is a significant milestone. I fully expect it will be the first of many,” as the collaboration aims to accelerate neurotechnology innovation, reduce barriers to entry and support a broader ecosystem of partners focused on transformative BCI solutions.
